News & Updates

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

01 Aug 2024 by

The JAK inhibitor upadacitinib brought sustained remission in the first 52 weeks of the phase III SELECT-GCA study of patients with new-onset or relapsing giant cell arteritis (GCA).

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

01 Aug 2024

Prior MI or stroke may predict diuretic use for HTN management

01 Aug 2024 by

A prespecified secondary analysis of the Diuretic Comparison Project (DCP) shows that when deciding between chlorthalidone (CTD) and hydrochlorothiazide (HCTZ) for the management of hypertension (HTN), a history of myocardial infarction (MI) or stroke may have to be considered.

Prior MI or stroke may predict diuretic use for HTN management

01 Aug 2024

First-line abatacept improves disease remission in RA

01 Aug 2024

The use of abatacept as a first-line biologic treatment appears to result in greater remission in rheumatoid arthritis (RA), especially if the drug is used continuously, as shown in a real-world study from Taiwan.

First-line abatacept improves disease remission in RA

01 Aug 2024

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024 by

Hysterosalpingography (HSG) with an oil-based contrast medium yields a significantly higher rate of ongoing pregnancy and live birth than HSG with a water-soluble contrast medium, according to a study presented at ESHRE 2024.

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024 by

In the treatment of genitourinary syndrome of menopause (GSM), the nonhormone alternative vaginal hyaluronic acid is equally efficacious as the treatment standard vaginal oestrogen, while being well-tolerated, as shown in a pilot study.

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024 by

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

Treatment with antiplatelet medications and age are some of the factors associated with the occurrence of radiation proctitis in patients with locally advanced cervical cancer treated by chemoradiation, a recent study has shown.

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024 by

In the 3-year updated analysis of the phase III TOPAZ-1 study, the combination of durvalumab and gemcitabine-cisplatin (GC) chemotherapy continues to deliver an overall survival (OS) benefit in individuals with biliary tract cancer (BTC).

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

A more selective risk-based approach to an enoxaparin thromboprophylaxis protocol appears to reduce the incidence of wound hematomas without increasing the rates of postpartum venous thromboembolism (VTE), as shown in a retrospective study.

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

Upadacitinib promising in first 52 weeks of SELECT-GCA trial

Prior MI or stroke may predict diuretic use for HTN management

Prior MI or stroke may predict diuretic use for HTN management

First-line abatacept improves disease remission in RA

First-line abatacept improves disease remission in RA

Infertile women may benefit from oil-based contrast during HSG

Infertile women may benefit from oil-based contrast during HSG

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Is it unsafe to use GLP-1 RAs in early pregnancy?

Is it unsafe to use GLP-1 RAs in early pregnancy?

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection